Clinical outcome and potential benefits of post-progression immunotherapy for patients with metastatic NSCLC with primary resistance to ipilumumab and nivolumab in the LONESTAR phase III study.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Mehmet Altan, Dawen Sui, Saumil Gandhi, Stephen Swisher, Natalie I Vokes, Mara Antonoff, Jianjun Zhang, George R. Blumenschein, Tina Cascone, Yasir Y Elamin, Carl Michael Gay, Don Lynn Gibbons, Xiuning Le, Marcelo Vailati Negrao, Ferdinandos Skoulidis, Anne S. Tsao, Janet Chen Tu, Amy R. Spelman, J. Jack Lee, John Heymach
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4282012688